Neelkanth Drugs Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 15-05-2024
- Paid Up Capital ₹ 2.90 Cr
as on 15-05-2024
- Company Age 25 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.62 M
as on 15-05-2024
- Satisfied Charges ₹ 212.93 Cr
as on 15-05-2024
- Revenue 38.28%
(FY 2023)
- Profit -44.75%
(FY 2023)
- Ebitda 26.08%
(FY 2023)
- Net Worth 0.55%
(FY 2023)
- Total Assets -78.19%
(FY 2023)
About Neelkanth Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.90 Cr.
The company currently has active open charges totaling ₹6.62 M. The company has closed loans amounting to ₹212.93 Cr, as per Ministry of Corporate Affairs (MCA) records.
Pramod Sharma, Arvind Venkat, Yashwant Singh, and One other member serve as directors at the Company.
- CIN/LLPIN
U24233TS1999PTC173960
- Company No.
099355
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 Apr 1999
- Date of AGM
09 Aug 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
East Delhi, Delhi, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Neelkanth Drugs Private Limited offer?
Neelkanth Drugs Private Limited offers a wide range of products and services, including Industrial Chemicals & Supplies, Chemical Intermediates, Anti Infective Drugs & Medicines, Antibiotic Tablets, Capsule & Syrup, Chemical Reagents & Catalysts, Inorganic Salts.
Who are the key members and board of directors at Neelkanth Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pramod Sharma  | Managing Director | 15-Oct-2004 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Arvind Venkat | Nominee Director | 29-Jun-2011 | Current |
| Yashwant Singh | Nominee Director | 31-Jul-2018 | Current |
| Vardaan Sharma | Director | 31-Aug-2017 | Current |
Financial Performance and Corporate Structure Insights of Neelkanth Drugs.
Neelkanth Drugs Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 38.28% increase. The company also saw a substantial fall in profitability, with a 44.75% decrease in profit. The company's net worth moved up by a moderate rise of 0.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Neelkanth Drugs?
In 2022, Neelkanth Drugs had a promoter holding of 100.00%. The company had 2 Subsidiaries and 1 Associate company. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 16 Sep 2017 | ₹6.30 M | Open |
The Nainital Bank Limited Creation Date: 12 Aug 2011 | ₹0.32 M | Open |
Hdfc Bank Limited Creation Date: 29 Jun 2020 | ₹90.00 Cr | Satisfied |
How Many Employees Work at Neelkanth Drugs?
Neelkanth Drugs has a workforce of 467 employees as of May 10, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Neelkanth Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Neelkanth Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
